Dauntless Investment Group LLC Makes New Investment in Coya Therapeutics, Inc. (NASDAQ:COYA)

Key Points

• Dauntless Investment Group LLC acquired 167,378 shares of Coya Therapeutics, Inc. during the 1st quarter, valued at approximately $1,083,000, making it the company's 8th largest position.
• Coya Therapeutics reported earnings of ($0.44) per share in the last quarter, with revenue of $257.88 million, far exceeding the consensus estimate.
• Wall Street analysts are generally optimistic about Coya Therapeutics, with an average rating of "Moderate Buy" and an average target price of $16.50.

Dauntless Investment Group LLC purchased a new stake in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 167,378 shares of the company's stock, valued at approximately $1,083,000. Coya Therapeutics accounts for 1.3% of Dauntless Investment Group LLC's holdings, making the stock its 8th largest position. Dauntless Investment Group LLC owned approximately 1.00% of Coya Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in shares of Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after buying an additional 4,777 shares during the period. XTX Topco Ltd acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $74,000. Northern Trust Corp grew its holdings in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after buying an additional 3,099 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Coya Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock valued at $863,000 after buying an additional 8,267 shares during the period. Institutional investors and hedge funds own 39.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Thursday, July 24th. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Tuesday, July 1st. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, June 9th. Lake Street Capital initiated coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Coya Therapeutics Trading Up 1.7%

Shares of Coya Therapeutics stock traded up $0.10 during trading hours on Friday, reaching $6.05. 33,211 shares of the company's stock were exchanged, compared to its average volume of 76,768. The company has a 50 day moving average of $5.86 and a two-hundred day moving average of $6.05. Coya Therapeutics, Inc. has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The stock has a market cap of $101.22 million, a P/E ratio of -5.65 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The business had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million. As a group, analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.